American journal of translational research最新文献

{"title":"Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan.","authors":"Ping Luo, Wei Ao, Yanjiao Ren, Dikai Xiang","doi":"10.62347/SHSZ3751","DOIUrl":"10.62347/SHSZ3751","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>From January 2018 to December 2021, 63 hospitalized patients diagnosed with HF following acute myocardial infarction (AMI) were enrolled in this prospective clinical trial. The observation group was comprised of 31 patients treated with sacubitril/valsartan (LCZ696) sodium tablets, while the control group, including 32 patients, received enalapril maleate tablets. All patients received standard HF therapy, including water-soluble aspirin, hydroclopidogrel sulfate, once-daily bivalirudin calcium, twice-daily metoprolol tartrate (dose titrated based on heart rate), once-daily spironolactone (dose adjusted for electrolytes), and once-daily dehydroimidazole (dose adjusted for electrolytes). HF symptom control, N-terminal B-type natriuretic peptide precursor (NT-proBNP) levels, cardiac anatomical parameters, heart rate, blood pressure, and 6-minute walking distance over a 90-day follow-up were assessed. The study is registered under ClinicalTrials.gov [ChiCTR2100042944].</p><p><strong>Results: </strong>On the 30th day post-discharge, the observation group exhibited a marked decrease in NT-proBNP levels and an improvement in left ventricular end-diastolic diameter, in contrast to the control group (both P<0.05). By the 90th day, the observation group showed significant improvements in left ventricular ejection fraction and left ventricular end-systolic diameter index, along with reduced blood pressure and serum creatinine levels (all P<0.05). Furthermore, the observation group displayed a more favorable New York Heart Association class distribution and enhanced performance in the 6-minute walk test (both P<0.05). No significant difference in the incidence of major adverse cardiovascular events was observed between the two groups during the 90-day follow-up period (P>0.05).</p><p><strong>Conclusion: </strong>Our findings indicate that sacubitril/valsartan (LCZ696) Sodium Tablets effectively enhance ventricular remodeling and cardiac function in patients with HF post-AMI, following a short-term treatment regimen. This therapeutic approach holds promise for improving clinical outcomes in this patient population.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5865-5879"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Warming acupuncture-moxibustion combined with Bushen Qianggu Recipe effectively improves bone metabolism in osteoporosis patients.","authors":"Lei Zhang, Fang Hu, Keqin Li, Lei Cao, Jin Zhang, Tian Xie, Min Zhao","doi":"10.62347/ECHR4598","DOIUrl":"https://doi.org/10.62347/ECHR4598","url":null,"abstract":"<p><strong>Background: </strong>Osteoporosis (OP) increases the risk of fractures in older adults, with no effective treatment options at present.</p><p><strong>Objectives: </strong>To analyze the effects of warming acupuncture-moxibustion (WAM) combined with Bushen Qianggu Recipe on bone metabolism, bone mineral density (BMD), and pain intensity in OP patients.</p><p><strong>Methods: </strong>This retrospective study involved 103 patients with OP who were admitted to Wuhan Hospital of Traditional Chinese Medicine between July 2021 and December 2023. The control group consisted of 47 cases given WAM and the research group consisted of 56 cases receiving WAM + Bushen Qianggu Recipe (Rehmanniae Radix 15 g, Radix Rehmanniae Preparata 15 g, Poria cocos 10 g, yam 10 g, rhizoma alismatis 10 g, raspberry 10 g, medlar 10 g, Schisandra chinensis 10 g, Semen Cuscutae 10 g, Epimedium 10 g, Polygonatum sibiricum Red. 10 g, Drynaria 10 g, and Eucommia ulmoides 10 g). Bone metabolism markers (procollagen type I N-terminal propeptide (PINP) and bone-specific alkaline phosphatase (B-ALP)), BMD (lumbar vertebrae at L_2-4, femoral neck, and distal 1/3 of the radius), pain intensity (visual analog score (VAS)), dysfunction (Oswestry Dysfunction Index), quality of life (Short-Form 36 Item Health Survey (SF-36)), and overall treatment efficacy were analyzed comparatively.</p><p><strong>Results: </strong>Compared with the baseline (before treatment) and post-treatment levels in the control group, the research group showed a reduction in PINP and B-ALP, an increase in BMD at the lumbar vertebrae L_2-4, femoral neck, and distal 1/3 of the radius, and a decrease in VAS and Oswestry Disability Index scores. Additionally, the research group performed better across various dimensions of the SF-36 scale and had a higher overall effective rate.</p><p><strong>Conclusions: </strong>WAM combined with Bushen Qianggu Recipe is effective in alleviating pain intensity and improving bone metabolism, BMD, and quality of life in OP patients; therefore it is deserving of clinical promotion.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"5106-5113"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of AFP-L3 and Des-γ-carboxy prothrombin in advanced primary liver cancer treated with Sorafenib and transarterial chemoembolization.","authors":"Shiwen Tang, Hao Liu, Peiyang Chen, Jiaqing He, Haiwei Chen, Jingqi Chen, Yanli Liu","doi":"10.62347/PMYP4404","DOIUrl":"https://doi.org/10.62347/PMYP4404","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the prognostic value of serum alpha-fetoprotein (AFP-L3) and Des-γ-carboxy prothrombin (DCP) in advanced primary liver cancer (PLC) undergoing combined treatment with Sorafenib and transarterial chemoembolization (TACE).</p><p><strong>Methods: </strong>This retrospective analysis included 82 patients with advanced PLC treated at the Second Affiliated Hospital, Guangzhou Medical University from January 2018 to January 2020. The patients were divided into an observation group (41 cases) and a control group (41 cases) based on their treatment method. The control group received TACE, while the observation group received a combination of Sorafenib and TACE. Both groups were evaluated after 12 weeks of treatment. Serum AFP-L3 and DCP levels were measured using a chemiluminescence immunoassay with magnetic particles. Short-term efficacy was compared between the two groups after 12 weeks of treatment. Additionally, Karnofsky Performance Status (KPS) scores, serum AFP-L3 and DCP levels before and after 12 weeks of treatment, and the survival rate after 2 years of follow-up were recorded. Serum AFP-L3 and DCP levels were compared between surviving and deceased patients.</p><p><strong>Results: </strong>The objective response rate in the observation group (68.29%) was higher than in the control group (46.34%) (P<0.05). KPS scores in both groups were significantly higher 12 weeks post-treatment compared to pre-treatment (P<0.05); the observation group had higher post-treatment KPS scores than the control group (P<0.05). Serum AFP-L3 and DCP levels were reduced in both groups after 12 weeks of treatment compared to pre-treatment levels (P<0.05). However, post-treatment serum AFP-L3 and DCP levels were lower in the observation group compared to the control group (both P<0.05). After 2 years of follow-up, the survival rate was higher in the observation group compared to the control group (P<0.05). AFP-L3 and DCP levels were higher in deceased patients compared to surviving patients after 2 years of follow-up (both P<0.05).</p><p><strong>Conclusion: </strong>Combination therapy with Sorafenib and TACE is effective for patients with advanced PLC, reducing AFP-L3 and DCP levels and improving patient survival rates. Additionally, higher levels of serum AFP-L3 and DCP are associated with poor prognosis.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"5004-5010"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for postoperative delirium in adult patients undergoing cardiopulmonary bypass in cardiac surgery.","authors":"Wanmin Pei, Huiling Tan, Tinghui Dai, Jian Liu, Yixun Tang, Jitong Liu","doi":"10.62347/TXAC6999","DOIUrl":"https://doi.org/10.62347/TXAC6999","url":null,"abstract":"<p><strong>Objective: </strong>To identify risk factors for postoperative delirium in adult patients undergoing cardiopulmonary bypass.</p><p><strong>Methods: </strong>The medical records of 214 patients who underwent cardiopulmonary bypass at the First Affiliated Hospital of Hunan Normal University from January 2022 to January 2024 were retrospectively analyzed. Based on the occurrence of postoperative delirium, patients were divided into a delirium group (49 cases) and a non-delirium group (165 cases). Outcome measures, including clinical baseline data, preoperative left ventricular ejection fraction (LVEF), preoperative Acute Physiology and Chronic Health Evaluation II (APACHE II) score, anesthesia duration, surgery duration, aortic cross-clamp duration, intraoperative mean arterial pressure (MAP), intraoperative blood loss, length of intensive care unit (ICU) stay, postoperative mechanical ventilation duration, as well as postoperative MAP, were compared between the two groups. Logistic regression analysis was performed to identify the potential factors associated with post-operative delirium in patients.</p><p><strong>Results: </strong>Of the included 214 patients, 49 patients experienced delirium, resulting in an incidence of 22.90%. The delirium group had significantly lower LVEF and significantly higher APACHE II scores compared to the non-delirium group (all P<0.001). No significant difference was observed between the two groups in terms of anesthesia duration, surgery duration, aortic cross-clamp duration, intraoperative MAP, and intraoperative blood loss (all P>0.05). The delirium group experienced significantly longer length of ICU stay and postoperative mechanical ventilation duration as compared to the non-delirium group (all P<0.001), but no significant difference was observed in terms of postoperative MAP between the two groups (P>0.05). Logistic regression analysis identified preoperative New York Heart Association classification (NYHA) (OR: 6.755, 95% CI: 2.529-18.039, P<0.001), preoperative LVEF (OR: 6.886, 95% CI: 2.383-19.899, P<0.001), preoperative APACHE II score (OR: 7.788, 95% CI: 2.740-22.135, P<0.001), length of ICU stay (OR: 9.463, 95% CI: 3.563-25.135, P<0.001), and postoperative mechanical ventilation duration (OR: 9.744, 95% CI: 3.419-27.768, P<0.001) as independent factors influencing the occurrence of delirium in adult patients undergoing cardiopulmonary bypass.</p><p><strong>Conclusion: </strong>Postoperative delirium is a prevalent complication among patients undergoing cardiac surgery. Independent risk factors for postoperative delirium in adult patients undergoing cardiopulmonary bypass during cardiac surgery include preoperative NYHA class III or IV, lower LVEF, higher APACHE II score, an extended length of stay in the ICU, and prolonged postoperative mechanical ventilation duration.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"4751-4760"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for varus knee osteoarthritis and their relationship with disease severity based on Kellgren-Lawrence classification.","authors":"Xiaohua Xue, Jianchi Li, Yuanqing Liang, Fanfan Cai, Zhongwei Zhao, Gang Liu","doi":"10.62347/YMJV4880","DOIUrl":"https://doi.org/10.62347/YMJV4880","url":null,"abstract":"<p><strong>Objective: </strong>To explore the hazard element of varus knee osteoarthritis (OA) and its relationship with Ailment severity based on the Kellgren-Lawrence classification.</p><p><strong>Methods: </strong>This study selected a cohort of patients who initially presented without clinical signs of arthritis and did not exhibit knee valgus or varus deformities when assessed from a hip-knee-ankle alignment perspective, focusing on the internal side. As the study progressed some individuals developed OA. Eligible participants were those who had undergone a standard whole lower extremity weight-bearing X-ray examination at our orthopedic outpatient clinic. The study period spanned from January 2021 to April 2022, and the selection criteria were strictly applied throughout this timeframe. Data on clinical and X-ray indices, including fibular head height, Kellgren-Lawrence grade, joint line convergence angle (JLCA), proximal medial tibial angle (MPTA), and Hip-knee-ankle angle, were collected from patients.</p><p><strong>Results: </strong>The study included 23 grade 0, 22 grade I, 32 grade II, 32 grade III, and 97 grade IV Kellgren-Lawrence classified patients. Significant differences in age, gender, and BMI were observed across groups (all P<0.05). With increasing OA severity, fibular head height and MPTA decreased, while JLCA and Hip-knee-ankle angle increased significantly (all P<0.05). Patients with OA exhibited larger fibular head height and MPTA but smaller JLCA and Hip-knee-ankle angle than those without arthritis (all P<0.05). Logistic regression analysis confirmed age, fibular head height, MPTA, JLCA, and Hip-knee-ankle angle as independent risk factors for varus knee OA (all P<0.05). Additionally, there was a strong positive correlation between age and fibular head height with disease severity, but a strong negative correlation between Hip-knee-ankle angle and disease severity (all P<0.05).</p><p><strong>Conclusion: </strong>Patients with varus knee OA have larger fibular head height and MPTA than those without arthritis. Age, fibular head height, and Hip-knee-ankle angle are risk factors for the development of varus knee OA. The severity of arthritis and varus deformity increases with age and fibular head height.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"4912-4919"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD34+ cell dose and CMV viremia after haploidentical hematopoietic stem cell transplantation: a retrospective study.","authors":"Peirou Yan, Xinan Pan, Qi Hao, Jingbo Wang","doi":"10.62347/SOPM3064","DOIUrl":"https://doi.org/10.62347/SOPM3064","url":null,"abstract":"<p><strong>Background: </strong>Patients with hematologic malignancies who undergo Haplo-HSCT (Haploidentical hematopoietic stem cell transplantation) are at a significantly higher risk for CMV (Cytomegalovirus) infection than individuals with normal immune function. This increased susceptibility to CMV is a major contributor to the morbidity and mortality seen in patients following hematopoietic stem cell transplantation.</p><p><strong>Methods: </strong>This study involved a retrospective analysis of 113 patients who underwent allogeneic hematopoietic stem cell transplantation for malignant hematological diseases. Relevant variables were assessed through univariate analysis, and those identified in the previous literature as potential influencers of the occurrence of CMV viremia were also included in the multivariate regression analysis.</p><p><strong>Results: </strong>Among the 113 patients with malignant hematologic diseases undergoing Haplo-HSCT, 56 cases (49.56%) were identified with CMV viremia. Initial univariate analysis highlighted patient age, graft source, and CD34+ cell dose as risk factors for CMV viremia post-transplantation. However, subsequent logistic regression analysis revealed that CD34+ cell dose stood out as an independent protective factor against CMV viremia (OR = 0.797, 95% CI: 0.644-0.987, P = 0.037).</p><p><strong>Conclusion: </strong>Our study reveals that a higher CD34 cell dosage serves as an independent protective factor against the development of CMV viremia after Haplo-HSCT in patients with hematologic malignancies.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"5130-5136"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of risk factors for pulmonary infection in acute ischemic stroke patients following intravenous thrombolysis with alteplase.","authors":"Fei Liu, Jingfei Chen","doi":"10.62347/VZQQ5140","DOIUrl":"https://doi.org/10.62347/VZQQ5140","url":null,"abstract":"<p><strong>Objective: </strong>To identify the risk factors for pulmonary infection in acute ischemic stroke patients treated with intravenous thrombolysis using alteplase.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 110 acute ischemic stroke patients who received intravenous alteplase thrombolysis between January 2019 and November 2022. The patients were categorized into a pulmonary infection group (40 cases) and a non-infection group (70 cases).</p><p><strong>Results: </strong>Multivariate logistic regression analysis identified the following independent risk factors for pulmonary infection: age, National Institutes of Health Stroke Scale (NIHSS) score at admission, underlying lung disease, hypertension, mechanical ventilation, aspiration, confusion, and elevated C-reactive protein (CRP) levels (all P<0.05). The sensitivity and specificity of CRP ifor predicting pulmonary infection were 88.57% and 75.00%, respectively. The NIHSS score demonstrated a sensitivity of 87.14% and a specificity of 70.00%. Further stratification of patients into a good prognosis group (75 cases) and a poor prognosis group (35 cases) revealed that high NIHSS scores at admission, increased fibrinogen (FIB) levels, a thrombolysis window exceeding 3 hours, and concurrent pulmonary infection were independent risk factors for poor prognosis. The area under the ROC curve for NIHSS in predicting prognosis was 0.890, and for FIB, it was 0.854 (P<0.001). The sensitivity and specificity of NIHSS for predicting poor prognosis were 89.33% and 82.86%, respectively, while for FIB, they were 84.00% and 82.86%.</p><p><strong>Conclusions: </strong>These findings indicate that factors such as age, NIHSS score, underlying lung disease, hypertension, and elevated CRP levels significantly contribute to the risk of pulmonary infection in acute ischemic stroke patients. Clinicians should closely monitor these values to manage the risk of pulmonary infection effectively.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"4643-4652"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between cognitive impairment and body composition indicators in patients with chronic kidney disease after hemodialysis.","authors":"Dan Yuan, Zhenxing Sun, Jingjing Zhou, Xiaoqi Wang, Zhongxin Li","doi":"10.62347/HFGL5701","DOIUrl":"https://doi.org/10.62347/HFGL5701","url":null,"abstract":"<p><strong>Objective: </strong>To examine the relationship between cognitive impairment and body composition indicators in chronic kidney disease (CKD) patients post-hemodialysis.</p><p><strong>Methods: </strong>This retrospective study included 110 CKD patients admitted to Beijing Luhe Hospital, Capital Medical University between January 2019 and January 2023. General clinical data and body composition indicators were compared between patients with and without cognitive impairment. Multiple logistic regression and ROC curve analysis were used to identify influencing factors and to develop a predictive model.</p><p><strong>Results: </strong>Cognitive impairment occurred in 50% of the patients post-hemodialysis. No significant differences were found in demographics, disease duration, comorbidities, or hemodialysis duration between the groups (all P > 0.05). However, significant differences were observed in body mass index (BMI) (P < 0.001), lean body mass index (LTI) (P = 0.007), fat tissue index (FTI) (P = 0.024), and total body water (TBW) (P < 0.001). Multiple logistic regression identified TBW (OR 4.900, 95% CI 3.062-7.511, P < 0.001), the TBW/extracellular water (ECW) ratio (OR 7.244, 95% CI 5.092-8.7613, P = 0.016), and the ECW/body cell mass (BCM) ratio (OR 6.720, 95% CI 4.564-8.692, P = 0.030) as independent risk factors for cognitive impairment post-hemodialysis. ROC analysis confirmed their predictive capacity, with AUC values of 0.840, 0.840, and 0.850 respectively. A predictive model incorporating these indicators was developed, showing good calibration (Hosmer-Lemeshow test, P = 0.912) and discrimination (C-index 0.974, 95% CI 0.952-0.997).</p><p><strong>Conclusion: </strong>Total body water, the TBW/ECW ratio, and the ECW/BCM ratio are independently associated with cognitive impairment in CKD patients post-hemodialysis. Body composition analysis serves as a valuable tool for predicting cognitive impairment in this population, guiding clinicians in assessing cognitive function and planning interventions for these patients.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"4504-4514"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early use of SGLT2 inhibitors reduces the progression of diabetic kidney disease: a retrospective cohort study.","authors":"Shaowei Pang, Xiaoli Li","doi":"10.62347/ARYA8831","DOIUrl":"https://doi.org/10.62347/ARYA8831","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors in preventing the progression of diabetic kidney disease and to provide guidance for clinical practice to improve renal health management strategies for diabetic patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 178 patients with diabetic kidney disease admitted to Baoji High Tech Hospital from March 2023 to March 2024. Of these, 88 patients who received early treatment with the SGLT2 inhibitor dapagliflozin were included in the early SGLT2-i group, while 90 patients receiving later treatment with SGLT2 inhibitor dapagliflozin were included in the late SGLT2-i group. Clinical data, overall effectiveness, adverse reactions, blood glucose, renal function, lipid levels, and inflammatory markers were compared between the two groups.</p><p><strong>Results: </strong>Prior to treatment, there were no differences in blood glucose indicators between the two groups (all P > 0.05). Following treatment, both groups showed reductions in 2-hour postprandial blood glucose (2hPG), fasting plasma glucose (FPG), and glycosylated hemoglobin (HbA1c), with the early SGLT2-i group demonstrating significantly lower values compared to the late SGLT2-i group (all P < 0.05). Similarly, there were no differences in renal function indicators between the two groups before treatment (all P > 0.05). However, following treatment, the early SGLT2-i group showed more noticeable improvements compared to the late SGLT2-i group (P < 0.05). Inflammatory markers and lipid levels followed similar patterns. The overall effectiveness of the early SGLT2-i group was higher than that of the late SGLT2-i group (92.05% vs. 78.89%, P < 0.05), while the incidence of adverse reactions did not differ statistically between the two groups (6.82% vs. 10.00%, P > 0.05).</p><p><strong>Conclusion: </strong>Early use of SGLT2 inhibitors in diabetic kidney disease patients effectively controls blood glucose and lipid levels, improves renal function, reduces inflammatory responses, and exhibits a low incidence of adverse reactions. This demonstrates high safety and an important role in delaying disease progression. Therefore, it is worth considering clinical promotion and use for this patient population.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"4967-4978"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of percutaneous vertebroplasty on the treatment of osteoporotic spinal fractures in elderly patients and risk factors for postoperative lower extremity deep vein thrombosis.","authors":"Jinpeng Chen, Gaochen Wu, Yiqi Miao, Lulu Wang, Fanjian Meng","doi":"10.62347/XELD8876","DOIUrl":"https://doi.org/10.62347/XELD8876","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness of PVP (PVP) in treating osteoporotic spinal fractures in the elderly and analyze the risk factors for postoperative deep vein thrombosis (DVT) in the lower extremities.</p><p><strong>Methods: </strong>A total of 100 elderly patients with osteoporotic spinal fractures, treated between August 2019 and July 2021, were divided into two groups: PVP (research group, n=50) and conservative treatment (control group, n=50). Outcome measures, including injured vertebrae, pain levels, and treatment outcomes, were retrospectively analyzed. Patients who underwent PVPs were further categorized based on the presence of lower extremity DVT one month post-surgery. Logistic regression analysis was used to identify risk factors for post-surgical lower limb DVT.</p><p><strong>Results: </strong>PVP resulted in a significantly smaller posterior convexity angle of the injured spine and higher anterior, midline, and posterior edges of the injured spine compared to conservative treatment (P<0.001). Patients in the research group had significantly lower visual analogue scale (VAS) scores and higher treatment efficiency compared to those in the conservative treatment group (all P<0.05). Nine cases of lower extremity DVT were observed after PVP. Logistic regression analysis identified age, body mass, smoking, and diabetes as independent risk factors for post-surgical lower extremity DVT.</p><p><strong>Conclusion: </strong>PVP improves spinal function and relieves pain in elderly patients with osteoporotic fractures. However, age, body mass, smoking, and diabetes are independent risk factors for postoperative lower extremity DVT.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 9","pages":"4796-4807"},"PeriodicalIF":1.7,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}